Evidence map›Paper›PMID 30357687›Full record

ReviewAdvances in experimental medicine and biology

The Role of Natural-Based Biomaterials in Advanced Therapies for Autoimmune Diseases.

Helena Ferreira, Joana F Fangueiro, Nuno M Neves

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Helena Ferreira *3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Guimarães, Portugal. helenaferreira@i3bs.uminho.pt.
Joana F Fangueiro *3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Guimarães, Portugal.
Nuno M Neves3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Guimarães, Portugal.
University of Minho · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune diseases (ADs) constitute a heterogeneous group of more than 100 pathophysiological conditions in which an immune response against the self is observed. The incidence and prevalence of these chronic diseases are increasing with inherently high social and economic impacts. The currently available therapies generally focus on reducing the activity of the immune system and, therefore, can present severe side effects such as enhanced patient susceptibility to opportunistic infections. Advanced therapies emerged as promising treatments and with real curative potential for ADs. Additionally, the use of natural polymers to engineer gene therapies, cell therapies and/or tissue-engineered medicinal products presents specific advantages. Natural polymers present higher affinity with biological systems than synthetic polymers, and frequently have a chemical structure and motifs similar to those existing in the extracellular matrix of the tissues. They also have good biological performance, making them very strong candidates for advanced therapy medicinal products. This review discusses the therapeutic advances and provides demonstrative examples of the role of natural-based biomaterials for the development of advanced therapies for ADs.

Indexed as

Biocompatible MaterialsAutoimmune DiseasesExtracellular MatrixHumansPolymersTissue EngineeringBiocompatible MaterialsPolymersAdvanced therapiesAutoimmune diseasesCell therapyGene therapyNatural-based biomaterialsStem cells

Identifiers

PMID30357687
OpenAlexW2898276318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.